M-145

Milnacipran hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant^®

• Empirical Formula (Hill Notation): C₁₅H₂₃ClN₂O
• CAS Number: 101152-94-7
• Molecular Weight: 282.81
• EC Number: 200-659-6
• MDL number: MFCD27978092
• UNSPSC Code: 41116107
• PubChem Substance ID: 329817879
• NACRES: NA.24

Properties

• grade: certified reference material
• form: liquid
• feature: Snap-N-Spike^®/Snap-N-Shoot^®
• packaging: ampule of 1 mL
• manufacturer/tradename: Cerilliant^®
• concentration: 1.0 mg/mL in methanol (as free base)
• technique(s): gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• application(s): clinical testing
• format: single component solution
• storage temp.: −20°C
• SMILES string: CCN(CC)C([C@]1(C2=CC=CC=C2)C[C@@H]1CN)=O.Cl
• InChI: 1S/C15H22N2O.ClH/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12;/h5-9,13H,3-4,10-11,16H2,1-2H3;1H/t13-,15+;/m1./s1
• InChI key: XNCDYJFPRPDERF-PBCQUBLHSA-N

Description

General description

Milnacipran, sold under the brand names Savella^®, Ixel^®, Dalcipran^®, or Toledomin, is a serotonin-norepinephrine reuptake inhibitor (SNRI) used in the treatment of depression. In 2009, the US Food and Drug Administration (FDA) approved milnacipran for management of the chronic pain disorder fibromyalgia, making it only the third drug approved in the US for this indication besides duloxetine and pregabalin.

Application

• Anesthetic and Analgesic Applications of Milnacipran: Review on new serotonin-norepinephrine reuptake inhibitors, highlighting Milnacipran hydrochloride′s role in anesthetic and analgesic applications, discussing its impact on pain management strategies (Fanelli et al., 2021).


• Sustained Release Delivery System for Milnacipran: Development of a novel chitosan-polycaprolactone based mucoadhesive gastro-retentive drug delivery system for Milnacipran HCl, aimed at improving bioavailability and enhancing patient compliance (Hussain et al., 2020).


• Comparative Review of Levomilnacipran and Milnacipran: Analysis of Levomilnacipran′s effectiveness compared to Milnacipran in treating major depressive disorder, focusing on efficacy, tolerability, and patient outcomes (Gautam et al., 2019).


• Antidepressant Efficacy and Side Effects: Network meta-analysis of 21 antidepressants, including Milnacipran, assessing their side effect profiles and comparative tolerability in the acute treatment of major depression (Tomlinson et al., 2019).

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Dalcipran is a registered trademark of Pierre Fabre Medicament

Ixel is a registered trademark of Pierre Fabre Medicament

Savella is a registered trademark of Forest Laboratories, Inc.

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Safety Information

• Pictograms: GHS02,GHS06,GHS08
• Signal Word: Danger
• Hazard Statements: H225,H301 + H311 + H331,H370
• Precautionary Statements: P210 - P280 - P301 + P310 + P330 - P302 + P352 + P312 - P304 + P340 + P311
• Hazard Classifications: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• Target Organs: Eyes
• Storage Class Code: 3 - Flammable liquids
• WGK: WGK 1
• Flash Point(F): 49.5 °F - closed cup
• Flash Point(C): 9.7 °C - closed cup